A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation

Published:2019-10 Issue:40 Volume:98 Page:e17443
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Wang Huan,Mao Chenyu,Li Ning,Sun Liping,Zheng Yulong,Xu Nong

Funder

Zhejiang Provincial Science and Technology Project

National Health and Family Planning Commission Research Fund & Zhejiang Provincial Medical and Health Major Science and Technology Plan Project

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference13 articles.

1. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages;Gillen;PLoS Med,2010

2. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial;Combs;BMC Cancer,2013

3. Treatment of metastatic pancreatic adenocarcinoma: a review;Thota;Oncology (Williston Park),2014

4. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature;Liede;J Clin Oncol,2004

5. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma;Holter;J Clin Oncol,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review;Cancers;2023-12-21

2. Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?;Tumori Journal;2022-10-26

3. Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor;BMJ Case Reports;2021-09

4. PARP inhibition in treatment of pancreatic cancer;Expert Review of Anticancer Therapy;2020-09-16

5. The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer;Journal of Clinical Medicine;2020-04-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3